Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...

The trispecific antibody market is rapidly advancing, with 50+ candidates in clinical trials and first approvals expected by 2028. These next-gen immunotherapies target three distinct antigens, ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 ...

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...

OmniAb’s ($OABI) stock tumbled roughly 25% this week after financial results for Q4 reflected a mix of revenue growth ...

A Stanford-led team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is ...

Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, �lanc� aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...